« Back
Home /
LY2857785

LY2857785

Item no.	HY-12293-10mM
Manufacturer	MedChem Express
CASRN	1619903-54-6
Amount	10 mM/1 mL
Quantity options	100 mg 10 mM/1 mL 10 mg 1 mg 25 mg 2 mg 50 mg 5 mg
Category	Inhibitors & Compound Libraries Small Molecules
Type	Inhibitors
Specific against	other
Purity	99.92
Citations	[1]Yin T, et al. A novel CDK9 inhibitor shows potent antitumor efficacy in preclinical hematologic tumor models. Mol Cancer Ther. 2014 Jun;13(6):1442-56. Mol Cancer Ther. 2014 Jun;13(6):1442-56.
Smiles	CC(C1=C2C=C(C3=NC(N[C@H]4CC[C@H](NC5CCOCC5)CC4)=NC=C3)C=CC2=NN1C)C
ECLASS 10.1	32160490
ECLASS 11.0	32160490
UNSPSC	12000000
Alias	1619903-54-6
Shipping Condition	Room temperature
Available
Manufacturer - Type	Reference compound
Manufacturer - Applications	Cancer-Kinase/protease
Manufacturer - Targets	Apoptosis; CDK
Shipping Temperature	Room Temperature
Storage Conditions	-20°C, 3 years; 4°C, 2 years (Powder)
Molecular Weight	448.60
Product Description	LY2857785 is a type I reversible and competitive ATP kinase inhibitor against CDK9 (IC50 11 nM) and other transcription kinases CDK8 (IC50 16 nM), and CDK7 (IC50 246 nM).
Manufacturer - Research Area	Cancer
Solubility	DMSO: 10 mg/mL (ultrasonic; warming; heat to 80°C)
Manufacturer - Pathway	Apoptosis; Cell Cycle/DNA Damage
Isoform	CDK7; CDK8; CDK9
Clinical information	No Development Reported

Note: The presented information and documents (Manual, Product Datasheet, Safety Datasheet and Certificate of Analysis) correspond to our latest update and should serve for orientational purpose only. We do not guarantee the topicality. We would kindly ask you to make a request for specific requirements, if necessary.

All products are intended for research use only (RUO). Not for human, veterinary or therapeutic use.

Request Data Sheet

Request product datasheet

HY-12293-10mM-safety-datasheet.pdf